Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 13/20 | 0.48 |
| ▸ | F2 | P00734 | 8/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 8/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TNKS | O95271 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6777513 | 0.90 | F10 (0.45) | F10F2PRSS1GRM5DPP4 | |
| SCHEMBL6778082 | 0.86 | F10 (0.42) | F10F2PRSS1GRM5KMT2A | |
| SCHEMBL6780731 | 0.85 | F10 (0.46) | F10F2PRSS1GRM5KMT2A | |
| SCHEMBL6780268 | 0.85 | F10 (0.46) | F10F2PRSS1KMT2ARAB9A | |
| SCHEMBL6779963 | 0.85 | F10 (0.41) | F10F2PRSS1GRM5DPP4 | |
| SCHEMBL6778302 | 0.83 | POLB (0.45) | F10F2PRSS1KMT2ARAB9A | |
| SCHEMBL6778043 | 0.83 | F10 (0.61) | F10F2PRSS1KMT2ATNKS | |
| SCHEMBL6779801 | 0.81 | F10 (0.43) | F10F2PRSS1KMT2ARAB9A | |
| SCHEMBL6784222 | 0.81 | F10 (0.42) | F10GRM5KMT2ARAB9A | |
| SCHEMBL6779185 | 0.81 | MEN1 (0.47) | F10F2PRSS1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794507-B2 | Compounds that inhibit factor Xa activity | MORPHOCHEM AG (DE) | 2004-09-21 | — | — | US | disclosed |
| US-20030153510-A1 | Novel compounds inhibiting factor xa activity | CAPPI MICHAEL W (DE) | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153510-A1 | Novel compounds inhibiting factor xa activity | SERPINC1, F11, TFPI | F10 6/4885F2 7/4885PRSS1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.